We are the sum
of our values

Our most valuable asset is the difference we make in people's lives.

Life sciences should be about leveraging infrastructures as well as intellect.

Innovation is found in products, processes, people, and thinking.

Healthcare should be accessible, safe and empowering.

Anxiety should be removed at all cost from healthcare.

How insulin therapy
should feel like

Inspired by you. Et vous. Und Sie. En U. 和你。Och du. あなたも. És te. E tu. وأنت


We are a catalyst for research, development and commercialization of innovative life sciences products for the care and cure of the global community.


We believe that every individual should have the opportunity to receive healthcare that is respectful, safe, and empowering.


InsuJet™ Countries


Global InsuJet™ Offices


InsuJet™ Partners

Availability of the InsuJet™

Albania, Andorra, Armenia, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Croatia, Cyprus, Czech Republic (Czechia), Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Italy, Jordan, Latvia, Liechtenstein, Lithuania, Luxembourg, Macao, Malaysia, Malta, Monaco, Netherlands, New Zealand, Norway, Poland, Portugal, Qatar, Romania, San Marino, Saudi Arabia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Arab Emirates, United Kingdom.

Distributors of the InsuJet™

Meditrend International Pty Ltd
Email: sales@meditrend.com.au
Tel.: +61 411 519 104
Address: Ground Floor, 23 Milton Parade, Malvern VIC 3144 Australia

Fagron Belgium nv
E-mail: info@fagron.be
Tel.: 0032 800 128 80
Address: Venecoweg 20A 9810 Nazareth

Walid Import & Export Co.,
E-mail: info@walidimportandexport.com
Tel: +201000030520
Tel: +201110057195
Tel: +201026464862
Address: Mahlat Domina, Dekhlia, Egypt.

Medcordis Kereskedelmi Kft.
E-mail: medcordis@medcordis.hu
Tel.: +36 1 617 78 82
Address: 1134 Budapest, Csángó utca 36. 6/1.

Lotus Medco
E-mail: info@lotusmedco.com
Tel.: +98 21 2235 6106
Address: No 48, Ofogh building, 3rd Golestan alley, Farahzadi Blv, Saadat Abad, Tehran, Iran

Step Drug Store Company
E-mail: Info@step-jo.com
Tel.: +962 6 5233551
Address: Amman- Jordan / Shafa Badran, P.O Box 117 Amman 11934

Mosadex C.V.
E-mail: info@mosadex.nl
Tel.: +31 88 990 82 00
Address: De Weegschaal 14, 5215 MN, 's-Hertogenbosch

Khotwa Medical Company
E-mail: info@step-ksa.com
Tel.: + 966 11 275 3565
Address: 2444 King Abdul Aziz Branch Rd, Al Maseif, Riyadh, Kingdom of Saudi Arabia

XinYa Biotechnology

Spirit Healthcare
E-mail: info@spirit-healthcare.co.uk
Tel.: 0800 881 5423
Address: Spirit House, Saffron Way, Leicester, LE2 6UP, United Kingdom

For people.
By people.

The InsuJetTM community and medical professionals turn our scientific and medical discoveries into solutions for their life.

Meet the InsuJet

A bit of

InsuJet has been in development for over two decades. We have been gathering clinical data and market feedback, for over a decade. At this stage we are confident that we are in a position to revolutionize the entire needle-free market.

InsuJet™ hopes to improve the lives of millions of people as we continue to receive approval in numerous countries.

2004 - Development of the technology starts in the UK.

2008 - Market approvel of the SQ-Pen. The first generation of the current family of needle-free inulin injection devices.

2009 - Global IP rights of technology acquired.

2010 - EU market approval.

2011 - InsuJet™ is covered by NHS.

2011 - Launch of the InsuJet™ V1.

2011 - 1st Clinical study

Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology.

Diabetes Care, August 2011

2012 - HK and China (CFDA) approval.

2013 - 2nd Clinical study into Needle-Free Jet Injection with Diabetes technology.

2014 - Australia (TGA) & New Zealand approval.

Launch of InsuJet™ V3.

New clinical studies validate and emphesize the effectiveness of InsuJet™ for patients of both type 1 and 2 diabetes.

Brazil Approval.

Taiwan Approval.

InsuJet™ gets approval to sell in Malaysia.

InsuJet™ enters Middle East (KSA / JO)

Nugen MD acquires InsuJet™.

Canada HC approval.

Emergo appointed as UKRP.

InsuJet™ is signing new distributors in 10 new territories.

Go green.
Go InsuJet™.

Used needles are a massive environmental concern. In the US alone, 7.8 bilion needles are disposed of on an annual basis, and most are for insulin use.

To fight this, we must push back on the use of single-use disposables. For every InsuJetTM user, we eliminate more than 1000 needles per year! That saves a lot of biohazardous waste and the added environmental cost of its collection.

In many countries where needles are not properly collected and disposed off. The elimination of single-use disposables helps to protect our environment.

Building innovative products requires working with world-class manufacturing partners and skilled employees. Our suppliers operate some of the most technologically advanced manufacturing facilities on the planet, designed to perform at the level of precision and quality necessary to build our products.

To maintain the highest level of conformity of our processes, we implement a Quality Management System that complies with ISO 13485:2016, which stipulates the requirments for medical device manufacturers and its suppliers to design, produce, store, distribute and dispose of medical devices. Our QMS is certified by our Notified Body, LNE/GMED, ID No. 0459. The InsuJetTM needle-free administration system is certified under MDD 93/42/EEC (until October 26, 2024), and currently under assessment of EU MDR 2017/745.

Our mission is to make the medical profession a safer place. Where needle-stick injuries are a thing of the past. Any needle-stick injury can cause emotional stress to healthcare workers as they are potentially exposed to dangerous patogents transmitting possible chronic and hazardous diseases. such as Hepetitus B, C and HIV.

Hospitals and clinics are required to provide safe medical devices to not only their patients, but to also their staff, to provide a safe and low risk work environment. Just like medical device manufacturers, they are the required to reduce risks to the lowest possible levels. This means that they need to provide safe alternatives to needles if available. NSI's with insulin delivery devices are the most common of all NSI's, and can be avoided with the InsuJetTM.

To ensure the device is safe to use, the device comes with an important safety feature, which is the counter-pressure release mechanism. This mechanism is designed to only release when it is pushed with the front of the device toward the target administation site. This prevents accidental firing, and makes the device more safe to use than other needle-free devices on the market without this feature.

We commit to continue improving the safety of needle-free technology by commiting to the best practices in Risk Management, Clinical Evaluation, Usability Engineering and Post Market Surveillance. We conduct Post Market Clinical Follow up studies to actively collect feedback on the clinical peformance of the devices in the market, so can continue to improve, making needle-free technology better and safer with every generation of devices.

The InsuJetTM team and its suppliers are held to the highest standards of labor and human rights, health and safety, environmental stewardship, and ethics.

We take care of our employees, who are critical to the success of the company, as they possess the know-how and understanding on how to design, manufacture and sell innovative medical devices according to the state of the art.

We take care of our distributors, who are our most important link to the end-users of the device. We rely on them to, not only make the device available, but to provide you with the best instructions possible to start using the InsuJetTM. We also rely on them to support you, and provide us with important feedback of how our devices are performing in ther market.

But maybe most importantly we try to take care of our end-customers, our early adopters and brand advocates, who are critical to not just our success, but to the success of needle-free technology in general.

Our worldwide corporate operations consider a sustainable approach. Not just reducing the use of (biohazardous) needles and its collection.

Sustainability is at the forefront of what we do. This is reflected by the clear choice for durability as opposed to the common medical industry trend of using single-use disposables.

The InsuJet needle-free injector is spring powered, which is more sustainable than gas powered alternatives that are on the market. The spring can be re-set by simply winding your device, so the energy needed for every injection is provided by you! This does not require any external tools, such as reset boxes, as is seen in competitor devices.

Our devices are build to last, and we warrant that our devices are free of defects under normal conditions of use or storage and within the indicated lifetime and expiration date.

Get started with the
needle-free insulin
injection system.

ISO 13485






01. Compatibele insulinetypes: mens en dier; Snelwerkende insulines (bolus); Snelwerkende insuline-analogen; Reguliere menselijke insuline; Basale insulines; Intermediair werkend, gewoonlijk: NPH/Isofaan; Langwerkend, gewoonlijk: Glargine, detemir, degludec; Voormengsels (bijv. 30/70).

    02. In een gebruikersonderzoek antwoordde 78% van de respondenten dat ze InsuJet™ zouden aanbevelen aan anderen.

    03. In een gebruikersonderzoek antwoordde 40% van de respondenten dat ze merkten dat ze minder insuline gebruikten.

    04. Naaldvrije jet-injectie van snelwerkende insuline verbetert de vroege postprandiale glucosecontrole bij patiënten met diabetes. Diabeteszorg, oktober 2013.

    05. Body mass index en de werkzaamheid van naaldloze jet-injectie voor de toediening van snelwerkende insuline-analogen, een post-hocanalyse. Diabetes, obesitas en metabolisme, juli 2012.

    06. Verbeterd farmacokinetisch en farmacodynamisch profiel van snelwerkende insuline met behulp van naaldvrije jet-injectietechnologie. Diabeteszorg, augustus 2011

    07. Een pilotstudie om de verdraagbaarheid en apparaatvoorkeur te onderzoeken bij type 1 diabetes van Insuline Apart toegediend door InsuJet™ in vergelijking met subcutane injectie. Diabetestechnologie en -therapie, 2014.

    08. Zie medische kostenanalyse - Noord-Amerika, 2022 beschikbaar op de partnerpagina.

    09. Berekend op 4 injecties per dag met een injectienaald. 4 injecties per dag, elke dag van het jaar, levert op tot 1460 naalden per jaar bespaard op gebruik.

    *. De InsuJet™ is gekalibreerd voor U-100 insulines

    **. Naaldmaat 26-27 wordt vaak gebruikt voor subcutane injecties en heeft een diameter van ongeveer 0,40 - 0,45 mm. De opening van het InsuJet™-mondstuk heeft een diameter van ongeveer 0,15 mm, wat veel kleiner is dan conventionele naaldmeters die worden gebruikt voor subcutane insuline-injecties.

    ***. https://pubmed.ncbi.nlm.nih.gov PMID:18820853